miRNAs antagonistic to BDNF expression, such as miR-101 and miR-107, have been studied for the targeted treatment of prostate cancer, and the previously mentioned drugs, such as Cabozantinib, Larotrctinib, and Entrctinib, have been developed. The gene discussed is BDNF; the disease is prostate cancer.